NCT01163149View on ClinicalTrials.gov

Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Hypophosphatasia
Interventions
DRUG

asfotase alfa

Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)

DRUG

asfotase alfa

Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)

Trial Locations (3)

27710

Duke University Medical Center, Durham

63131

Shriner's Hospital for Children, St Louis

R3A 1S1

Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY